Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.


Trading Lessons

Mainstream Financial News

Archives

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates:

CRSP Buy Chardan Capital Markets

Cuts:

GPOR Underweight Morgan Stanley

Overnight Headlines By Ticker:

ABBV AbbVie Inc.

3/28 08:05 Announce new collaboration with M2Gen for ORIEN avatar research program

ACN Accenture plc

3/28 06:36 Awarded 5 year, $232M contract by GSA FEDSIM for (Read More….)

Accenture Awarded 5 Year $232 Million Contract by GSA FEDSIM

March 28, 2017: Accenture Federal Services has been awarded a five-year, $232 million contract to help the U.S. Marshals Service (USMS) implement its Mission Modernization Program, which will provide mobile capabilities and real-time decision-making with an enterprise data solution to improve data accessibility through an intuitive, user-centered design.

The new IT system that Accenture will (Read More….)

CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing

March 28, 2017: CRISPR Therapeutics reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates: None

Cuts: None

Overnight Headlines By Ticker:

ALXN Alexion Pharmaceuticals Inc.

3/27 08:16 JPMorgan Chase and Co Reiterates ALXN with Overweight

3/27 06:30 Names Ludwig Hantson as CEO, effective immediately

ATVI Activision Blizzard Inc

3/27 08:10 Morgan Stanley Reiterates ATVI with Overweight

CALM Cal-Maine (Read More….)

Activision Morgan Stanley Reiterates With Overweight

March 27, 2017: Morgan Stanley reiterates Activision Blizzard Inc with Overweight rating. Morgan Stanley says eSports deep dive finds a $100 million annual rev base case, driven by content licensing/ads/sponsors. This yields minimal upside, but firms $720 million rev bull case shows how eSports could be worth $11 per ATVI share. Firms new eSports-driven $71 (Read More….)

Market Alert! Brexit Coming as Trump Tax Cuts Delayed

This week’s show features commentary on the massive wave of retail stores closing, Brexit and Article 50 to be invoked on March 29, the chilling plunge in bank loan creation, President Trump’s flip on extending the debt ceiling, the fantasy Trump rally ending, the fake news Trump has ties with Russia and the Devin Nunes (Read More….)

Trader Alert! Get Out Of the Market!

The Republican health care bill was pulled as Republicans say they didn’t have the votes needed to pass it.

Get out of the market as it’s better to be safe than sorry. Will talk more about this in this weekend’s Saturday show.

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

HURN Market Outperform Avondale Partners VRTU Outperform Cowen & Co.

Initiates: None

Cuts: None

Overnight Headlines By Ticker:

A Agilent Technologies, Inc

3/23 18:17 Positive Mad Money mention – CNBC

ALRM Alarm.com

3/23 17:25 ABS Capital Partners V Trust discloses amended 11.55% stake – 13D/A filing

(Read More….)

EU Approves Amgen’s Amgevita

March 24, 2017: Amgen announced that the European Commission (EC) has granted marketing authorization for AMGEVITA (biosimilar adalimumab) in all available indications.

AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic (Read More….)

Medicare Announces Criteria Covering Dexcom G5 Mobile

March 24, 2017: DexCom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicare who have either Type 1 or Type 2 diabetes (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates: None

Cuts:

CNC Neutral CitiGroup Smith Barney GPOR Neutral Goldman Sachs & Co MO Underperform RBC Capital Markets

Overnight Headlines By Ticker:

ACN Accenture plc

3/23 06:59 Reports Q2 $1.33 v $1.30e, R$8.32B v $8.36Be

ALXN Alexion Pharmaceuticals Inc.

3/22 16:05 Submits application in (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

TECK Buy Berenberg

Initiates: None

Cuts:

TDG Market Perform Cowen & Co.

Overnight Headlines By Ticker:

GE General Electric Co

3/22 08:36 Targets FY17 Industrial operating profit $17.2B, Increases cost cuts by $1B in agreement with holder Trian which has intensified discussions in the last month (Read More….)

Scalping the Market In TZA For Quick Profits Using the Dark Pool

I’m in a scalp trade on TZA and watching the trades come in off the dark pool. As long as most of the trades off the dark pool are below their mid-range position, I’m holding the TZA position for quick profits.

GLD Daily Holdings Fall Rise 4.1 Tonnes to 834.4 Tonnes

March 21, 2017: StreetTracks Gold Trust SPDR Gold Trust ETF GLD daily holdings rise 4.1 tonnes to 834.4 tonnes; First rise since Mar 15th.

March 6, 2017: GLD StreetTracks Gold Trust SPDR Gold Trust ETF daily holdings fall 3.8 tonnes to 836.8 tonnes which is the lowest level since Feb 10th. This is the second (Read More….)

Teck Resources Gets Buy Rating From Berenberg

March 22, 2017: Berenberg raised Teck Resources to a Buy rating from Hold and set a price target of $27. Berenberg cites a tighter but well supplied copper market.

February 15, 2017: Teck Resources reports Q4 EPS of C$1.61 versus the C$0.03 y/y estimate. Revenue also beat coming in at C$3.56 billion versus the C$2.14 (Read More….)

Opko Receives FDA Orphan Drug Status For Oligonucleotide

March 22, 2017: OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome. Currently, there is no approved treatment for Dravet Syndrome in (Read More….)

Medtronic Receives FDA Approval For CoreValve

March 22, 2017: Medtronic Inc announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the heels of new 30-day clinical data that (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

TECK Buy Deutsche Banc Securities

Initiates: None

Cuts: None

Overnight Headlines By Ticker:

ACN Accenture plc

3/21 07:59 Acquires UK-based consulting services provider Focus Group Europe; terms undisclsoed

3/21 07:25 Cantor Fitzgerald Reiterates ACN with Overweight, price target: $135

ATNM Actinium Pharmaceuticals Inc

3/21 07:04 Announces (Read More….)

US Economy So Bad Many Retailers Won’t Make It To Next Holiday Season

A tsunami retail store closings is headed our way courtesy of the weak US economy and pathetic 2% GDP growth. I thought Democrats did such a good job with the economy… NOT!

The CEO of EBAY just got done saying on CNBC, “I’m not sure all retailers will make it to the next holiday season.”

(Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

ILMN Outperform Leerink Partners

Initiates: None

Cuts:

MBLY Neutral Piper Jaffray/Simmons

Overnight Headlines By Ticker:

ABT Abbott Laboratories

3/19 15:47 Late-breaking data shows Abbott’s CardioMEMS HF system is effective in reducing heart failure hospitalizations and cost of care

3/18 12:52 Late-breaking data on Abbott’s MitraClip® System (Read More….)

Mobileye May Seek Higher Offers From Other Companies

March 19, 2017: Mobileye may seek higher offers from other companies according to a report in the NY Post. Source: http://nypost.com/2017/03/18/intels-15b-deal-to-buy-self-driving-car-company-in-jeopardy/

**NOTE Mar 13th: Confirms to be acquired by Intel for $63.54/shr in cash valued at $15.3B; To be accretive to Intel EPS immediately

February 23, 2017: RBC reiterates Mobileye with an Outperform rating and (Read More….)

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)

Nektar Therapeutics NKTR-181 meets Primary and Secondary Endpoints in Phase 3

March 20, 2017: Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction (Read More….)